Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
about
Translating pharmacogenomics: challenges on the road to the clinicApplications of CYP450 testing in the clinical settingWarfarin reversalPharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinVKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarkerA prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical dataInvestigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of GujaratThe allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population.Expectations, validity, and reality in pharmacogenetics.CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Candidate gene case-control association studies: advantages and potential pitfalls.The future prospects of pharmacogenetics in oral anticoagulation therapy.Pharmacogenomics: marshalling the human genome to individualise drug therapyWarfarin toxicity and individual variability-clinical case.Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Impact of regular physical activity on weekly warfarin dose requirement.Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Novel anticoagulants in atrial fibrillation stroke preventionExposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosingPharmacogenetic testing: Current Evidence of Clinical Utility.Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.Warfarin pharmacogenomics in children.CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration.Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.New oral anticoagulants and the cancer patient.Genomic architecture of pharmacological efficacy and adverse events.Pharmacogenetics aspects of oral anticoagulants therapy.The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.CYP2C9 polymorphism and warfarin dose requirements.Warfarin: a case history in pharmacogenetics.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
P2860
Q21092371-659C18A5-1AA1-4ABE-9D1A-EEDEEB7663ADQ24621760-E58ED663-1EAB-4317-BDC6-C1E2984CB8BAQ24672566-75616239-A83A-4B66-90F7-FD9DDE6BC78AQ24814457-500D1605-02C8-4C60-923A-4BFD09A458E1Q27002899-C60C9091-DC9C-41AF-938B-E3BF633BEED7Q28276514-D07CF387-A927-4FE4-A3E4-AEB47BE706ABQ28476502-14705CFA-64E9-4C17-B45B-6E728B4E598DQ31004538-6F09C60B-C901-41DF-8474-6C4FD4483E31Q33555327-2B12A247-9E4A-4B9E-8E8D-824840EC90BBQ33782314-AFA67227-9D64-496A-A9BC-3E88C97DC494Q33926313-3BFD8D91-4A5B-421C-BF8F-77652720E45BQ33990359-4226448D-B951-4ECC-8E52-CCC933E843A6Q33990441-9C17981A-4268-4561-BE76-20E51BAF3D16Q34459045-3043C21B-BFDC-4CFF-A7D8-2FA18080F108Q34530230-F6B7CF97-2A87-4B15-B0B2-65B6123E5D0FQ35090217-2AB55F07-4287-49D2-AA7D-534A2E6B37F6Q35155651-CB6A7606-F143-48B4-B4FC-D39F7877DC8FQ35219654-DEA5CB0E-B089-44CE-8772-ADA562E5CE81Q35661209-F8FF4E84-1FBA-43CA-A801-1CD7A3B48E32Q35735988-7CDD31C6-C928-48CE-A581-43C6FB683151Q35826999-D4BF4BDF-FBD4-405B-9E8C-9E57F3552600Q35827687-280C221A-00D2-4BE4-B65C-5DB0CAF38F5BQ36441521-149E7C42-18F1-418C-9140-C2D8FFADAABDQ36443814-FEF0FD54-ADC5-4AC4-9E5D-0F8B8D44676CQ36921008-1710ADC8-F75A-4A8E-A728-DC933DDAE638Q37151528-552EF4F1-AEC7-49A0-A9AE-409EE1DB0EDCQ37160370-5083AB3B-D351-4237-9895-70E7041FB18DQ37195550-C831004C-E6C6-4548-BA9D-A11D2FAA3F65Q37205695-8637323A-F57F-4CFA-AAB9-D876D64E2318Q37249828-4EABAA18-6D24-430B-829F-4155F5994585Q37372721-1ABCE6B6-12C2-43EF-B8D6-9776A5AB6F43Q37454438-AF00C2AF-503C-4B65-ADAA-CF227F88617DQ37519054-33A30B23-A2C4-437B-A252-4684397F3811Q38292930-0154E091-74EF-436F-8F91-7330827423DAQ39469904-AD6D03DB-6684-4ECE-AEDA-E256AA1A455AQ41118521-F47C7BA1-BDE0-4742-BF87-4E97C7F8FD08Q42780491-4727BA3B-031A-4BFB-AFC1-E6388289027DQ43012628-1965B66A-3445-4B1C-9D9E-AD7E5B7B5A12Q47570862-9A13DE68-4C5D-47FD-82E4-A1B0072FE994
P2860
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Influence of cytochrome P-450 ...... tients on long-term treatment.
@en
Influence of cytochrome P-450 ...... tients on long-term treatment.
@nl
type
label
Influence of cytochrome P-450 ...... tients on long-term treatment.
@en
Influence of cytochrome P-450 ...... tients on long-term treatment.
@nl
prefLabel
Influence of cytochrome P-450 ...... tients on long-term treatment.
@en
Influence of cytochrome P-450 ...... tients on long-term treatment.
@nl
P2093
P1433
P1476
Influence of cytochrome P-450 ...... atients on long-term treatment
@en
P2093
P304
P407
P577
2000-09-01T00:00:00Z